A1C reduction on semaglutide: SUSTAIN program meta-analysis — anyone have experience?

CarlaRPh_TPA said:

Steady state is the thing most people miss.

This is exactly what I could not find anywhere else. Sending this to two other people who asked me the same thing last week.

From the other side of the consultation, briefly.

BethLabQueen said:

...but the FDA says semaglutide...

Interesting point. I want to add some regulatory nuance: the FDA labeling reflects the specific clinical trial data submitted for approval. Real-world clinical practice often extends beyond the FDA label based on emerging evidence and clinical judgment.

Example: semaglutide was first approved for diabetes (Ozempic), then obesity (Wegovy). The molecule didn't change — our understanding of its applications expanded. Similarly, semaglutide may evolve as more data accumulates.

DebRD_ATL said:

The mechanism that matters here is not stomach emptying, it is central.

Pushing back on DebRD_ATL here. The trial means are being read too generously in this thread. STEP populations were selected, supported, and titrated by protocol, and the real-world curves are consistently a few points worse. That difference is not noise, it is what happens when you remove the study infrastructure.

The figures, for anyone assembling their own picture. A quick sanity check on any figure quoted here: is it mean or median, is it intention-to-treat or completers, and what was the comparator. Three questions, and they resolve most disagreements in these threads.

Moderator note: leaving this open. It is being argued well and the disagreement is the useful part. Report rather than reply if it drifts again.